Moreover, the XT-I can be used as a biomarker to identify fibrotic processes in systemic sclerosis [29] or during fibrotic scarring as a biomarker for the myofibroblast differentiation [32]. This evidence concerns the gene XYLT1 and systemic sclerosis.